Developer docs
API playgroundTry for free, no card

Search company profiles

Resolve BioSciences

Full company profile

uuid00048qf

Namestring
Resolve BioSciences
Legal namestring
Resolve BioSciences GmbH
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Resolve BioSciences GmbH is a German life-sciences company founded in 2020 and headquartered in Monheim am Rhein that develops and commercializes Molecular Cartography, a spatial biology platform for high-resolution, multi-modal tissue analysis. The company serves pharmaceutical companies, academic research institutions, and clinical laboratories working in oncology, immuno-oncology, neurology, developmental biology, and therapeutics development, with peer-reviewed adoption documented in Nature, Cell, and Nature Biotechnology publications between 2022 and 2025.

The core technology is a single-molecule fluorescence in situ hybridization (smFISH) workflow with combinatorial labeling that enables detection of up to 330 RNA targets per tissue section on fresh-frozen or FFPE samples without tissue clearing or signal amplification. The product surface spans the MC1 and MC2 benchtop instrumentation platforms, a cyclic immuno-fluorescence protein assay capable of detecting over 10 protein markers per sample, and a software stack comprising ReCognize (web-based 3D expression visualization with cloud-based Seurat clustering and UMAP analysis) and Panel Design Studio (a tool for designing custom gene panels against the Human Protein Atlas). Cell boundary delineation is performed using deep-learning segmentation applied to targeted nuclear, cytoplasmic, and membrane staining.

Resolve Biosciences operates a direct, enterprise-focused go-to-market through an account-registered customer portal (my.resolvebiosciences.com) and an inside/field sales motion, monetizing Molecular Cartography services together with subscription-based access to ReCognize and related data-analysis tools. The company has raised over $100 million in venture capital, anchored by a $71 million Series B led by Patient Square Capital in October 2022, with additional backing from PS Capital Management, Alafi Capital, NRW.Venture, HTGF, Norgine, CD-Venture, NRW.Bank, and Enterprise Singapore. The company is led by CEO and Managing Director Dr. Axel Heinemann, with a leadership team spanning CTO (Dr. Markus Zumbansen), COO (Dr. Peter Grünefeld), CFO (Marko Labus), and CPO (Meike Bongers), and Peer Schatz (PS Capital) as Chairman.

Short descriptiontext

Resolve BioSciences is a German spatial biology company commercializing its Molecular Cartography platform — a single-molecule FISH system for multi-modal tissue profiling of RNA, protein, and morphology — serving pharmaceutical companies, academic research institutions, and clinical laboratories in oncology and therapeutics development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMonheim am Rhein, Germany
HQ citystring
Monheim am Rhein
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology, spatial transcriptomics, molecular cartography, single-molecule FISH, spatial proteomics
Industry4 codes
PRIMARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Services-Commercial Physical & Biological Research8731
Product category
Spatial Biology / Spatial Transcriptomics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Molecular Cartography Platform Services
TypeSubscription Recurring
Description

Revenue generated from providing spatial biology analysis services using the Molecular Cartography platform, including RNA and protein assays, data visualization, and support services for research and clinical applications

biospace.com
2Software and Data Analysis Tools
TypeSubscription Recurring
Description

Access to cloud-based data analysis and visualization tools including ReCognize platform for spatial transcriptomics data analysis

my.resolvebiosciences.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Customer accounts with registration required
ModelSubscriptionBilling cadenceAnnual
Notes

Account-based access requiring registration and approval process. Customers apply via email to request accounts for Molecular Cartography data services.

my.resolvebiosciences.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Molecular Cartography™
Description

The company's core technology platform for multi-modal spatial profiling with unparalleled sensitivity and specificity, providing true single-molecule RNA fluorescence in situ hybridization for spatial biology analysis.

resolvebiosciences.com
+1 more record
Core offering1 text field

Resolve BioSciences delivers a Molecular Cartography™ spatial biology platform built on single-molecule fluorescence in situ hybridization (smFISH), enabling high-resolution, multi-modal profiling of RNA (up to 330 targets), protein (10+ markers), and H&E morphology on the same tissue section without tissue clearing or signal amplification. Offerings include the MC1 and MC2 benchtop instruments, RNA and protein assays, deep learning–based cell segmentation, the ReCognize cloud-based 3D visualization application, and the Panel Design Studio for custom gene panel creation. The company provides these capabilities primarily as fee-for-service spatial biology analysis and through subscription access to its software tools for life sciences researchers and pharmaceutical developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Detection of up to 330 RNA targets per tissue section in single run
+2 more records
Product overview1 text field

Resolve BioSciences offers Molecular Cartography, a spatial biology platform comprising hardware instruments (MC1 and MC2 benchtop platforms) and a suite of complementary software tools. The platform is built on single-molecule fluorescence in situ hybridization (smFISH) and provides multi-modal profiling of RNA, protein, and morphology on the same tissue section. Software offerings include ReCognize for 3D data visualization and cloud-based single-cell analysis, and Panel Design Studio for custom gene panel creation. The company was founded in 2020 and is headquartered in Monheim am Rhein, Germany.

Product and service7 records
1Molecular Cartography
CategorySpatial biology platform
Description

A spatial biology platform based on single-molecule fluorescence in situ hybridization (smFISH) that delivers high-resolution, multi-modal tissue analysis for disease pathology, neurology, oncology, and developmental biology research. Supports simultaneous profiling of RNA (up to 330 targets), protein (over 10 markers), and morphology (H&E) on the same tissue section without tissue clearing or signal amplification; intended for research institutions, pharmaceutical companies, and academic laboratories.

2MC1 Benchtop Platform
CategoryBenchtop spatial imaging instrument
Description

First-generation benchtop instrument of the Molecular Cartography platform for spatial molecular imaging, performing targeted RNA and protein assays on tissue samples with high sensitivity and specificity. Used by research institutions, pharmaceutical companies, and academic laboratories performing spatial biology experiments.

3MC2 Next-Generation Benchtop Platform
CategoryBenchtop spatial imaging instrument
Description

Next-generation benchtop instrument of the Molecular Cartography platform offering expanded scanning area, increased plexity, targeted panel content, advanced controls, and true multi-modality compared to MC1. Designed for next-generation pathology workflows in research and translational settings.

4ReCognize
CategoryCloud-based spatial data visualization and analysis software
Description

Web-based, all-in-one data visualization and analysis application for Molecular Cartography data. Browses expression data in 3D, automatically builds cell-by-gene expression matrices from uploaded ROI files, performs cell clustering via Seurat in the cloud, generates UMAP visualizations, heatmaps, and exports annotated images and CSV transcript counts. Accessed by registered customers through the My Resolve portal.

5Panel Design Studio
CategoryCustom gene panel design software
Description

Web-based design tool within the My Resolve portal for building custom gene panels by selecting genes, defining probe-sets, and simulating theoretical expression levels across human tissues and cell types using data from The Human Protein Atlas. Used by researchers designing Molecular Cartography RNA experiments.

6Molecular Cartography RNA Assay
CategorySpatial transcriptomics assay
Description

Spatial transcriptomics assay that uses in-silico designed probes and combinatorial labeling across multiple rounds of hybridization and imaging to detect up to 330 RNA targets per tissue section at subcellular resolution, applied in tumor biology, neurology, and developmental biology research.

7Molecular Cartography Protein Assay
CategorySpatial proteomics assay
Description

Cyclic immuno-fluorescence workflow detecting over 10 protein markers per sample, complementing RNA data for multi-omic analysis ranging from investigational to routine clinical applications, applied in tumor pathology and immuno-oncology research.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in spatial biology with Xenium (in situ) and Visium (capture-based) platforms; serves overlapping pharma and academic customers and is the most commercially entrenched player in the spatial transcriptomics market.

TypeDirect peer
Description

Direct competitor offering GeoMx digital spatial profiling and cosMx high-plex in situ platform; targets the same oncology, immuno-oncology, and translational research customer base as Resolve.

TypeDirect peer
Description

Direct competitor based on MERFISH technology for high-plex spatial transcriptomics; competes head-to-head with Resolve's Molecular Cartography in academic and pharma research accounts.

TypeDirect peer
Description

Direct competitor in spatial biology offering the PhenoCycler (CODEX) and PhenoImager platforms for multiplexed protein and RNA spatial analysis; serves overlapping translational and pharma customers.

5Rebus Biosystems
TypeEmerging player
Description

Emerging spatial transcriptomics player offering the Rebus Esper instrument with a focus on high-plex, single-cell-resolution spatial RNA profiling; competes with Resolve in research-use accounts.

TypeBroad incumbent
Description

Broader life-science tools incumbent with RNAscope in situ hybridization technology and a portfolio spanning reagents, instruments, and spatial biology assets (including acquired brands); competes with Resolve in the spatial RNA workflow layer.

TypeBroad incumbent
Description

Diversified scientific instrument maker that has expanded into spatial biology through acquisitions (e.g., NanoString's spatial assets); competes with Resolve as a broad incumbent entering the spatial transcriptomics market.

TypeBroad incumbent
Description

Life-science tools company with mass cytometry and spatial biology offerings; less direct overlap but competes for the same translational and pharma research budgets as Resolve.

TypeBroad incumbent
Description

Sequencing giant with downstream spatial-adjacent offerings (e.g., partnerships and DRAGEN software for spatial data); represents both a potential partner and a competitive threat given its reach into pharma genomic workflows.

TypeEmerging player
Description

Emerging spatial biology and multi-omics platform player with the G4 sequencing platform and spatial initiatives; partial overlap with Resolve in spatial transcriptomics-adjacent workflows.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Resolve BioSciences

Spatial Biology / Spatial Transcriptomicsresolvebiosciences.com

Resolve BioSciences is a German spatial biology company commercializing its Molecular Cartography platform — a single-molecule FISH system for multi-modal tissue profiling of RNA, protein, and morphology — serving pharmaceutical companies, academic research institutions, and clinical laboratories in oncology and therapeutics development.

What Resolve BioSciences does

Resolve BioSciences GmbH is a German life-sciences company founded in 2020 and headquartered in Monheim am Rhein that develops and commercializes Molecular Cartography, a spatial biology platform for high-resolution, multi-modal tissue analysis. The company serves pharmaceutical companies, academic research institutions, and clinical laboratories working in oncology, immuno-oncology, neurology, developmental biology, and therapeutics development, with peer-reviewed adoption documented in Nature, Cell, and Nature Biotechnology publications between 2022 and 2025.

The core technology is a single-molecule fluorescence in situ hybridization (smFISH) workflow with combinatorial labeling that enables detection of up to 330 RNA targets per tissue section on fresh-frozen or FFPE samples without tissue clearing or signal amplification. The product surface spans the MC1 and MC2 benchtop instrumentation platforms, a cyclic immuno-fluorescence protein assay capable of detecting over 10 protein markers per sample, and a software stack comprising ReCognize (web-based 3D expression visualization with cloud-based Seurat clustering and UMAP analysis) and Panel Design Studio (a tool for designing custom gene panels against the Human Protein Atlas). Cell boundary delineation is performed using deep-learning segmentation applied to targeted nuclear, cytoplasmic, and membrane staining.

Resolve Biosciences operates a direct, enterprise-focused go-to-market through an account-registered customer portal (my.resolvebiosciences.com) and an inside/field sales motion, monetizing Molecular Cartography services together with subscription-based access to ReCognize and related data-analysis tools. The company has raised over $100 million in venture capital, anchored by a $71 million Series B led by Patient Square Capital in October 2022, with additional backing from PS Capital Management, Alafi Capital, NRW.Venture, HTGF, Norgine, CD-Venture, NRW.Bank, and Enterprise Singapore. The company is led by CEO and Managing Director Dr. Axel Heinemann, with a leadership team spanning CTO (Dr. Markus Zumbansen), COO (Dr. Peter Grünefeld), CFO (Marko Labus), and CPO (Meike Bongers), and Peer Schatz (PS Capital) as Chairman.

Resolve BioSciences firmographics

Firmographics
Name
Resolve BioSciences
Legal name
Resolve BioSciences GmbH
Website
https://resolvebiosciences.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Resolve BioSciences is a German spatial biology company commercializing its Molecular Cartography platform — a single-molecule FISH system for multi-modal tissue profiling of RNA, protein, and morphology — serving pharmaceutical companies, academic research institutions, and clinical laboratories in oncology and therapeutics development.
Ownership category
akta.pro rank

Resolve BioSciences industry classification

Industry
Product category
Spatial Biology / Spatial Transcriptomics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Spatial biology
  • Spatial transcriptomics
  • Molecular cartography
  • Single-molecule FISH
  • Spatial proteomics

Where Resolve BioSciences is headquartered

Location

Headquarters

HQ city
Monheim am Rhein
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Resolve BioSciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Molecular Cartography Platform Services: Revenue generated from providing spatial biology analysis services using the Molecular Cartography platform, including RNA and protein assays, data visualization, and support services for research and clinical applications
  2. Software and Data Analysis Tools: Access to cloud-based data analysis and visualization tools including ReCognize platform for spatial transcriptomics data analysis

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCustomer accounts with registration required

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Resolve BioSciences product offering

Product offering

Core offering

Resolve BioSciences delivers a Molecular Cartography™ spatial biology platform built on single-molecule fluorescence in situ hybridization (smFISH), enabling high-resolution, multi-modal profiling of RNA (up to 330 targets), protein (10+ markers), and H&E morphology on the same tissue section without tissue clearing or signal amplification. Offerings include the MC1 and MC2 benchtop instruments, RNA and protein assays, deep learning–based cell segmentation, the ReCognize cloud-based 3D visualization application, and the Panel Design Studio for custom gene panel creation. The company provides these capabilities primarily as fee-for-service spatial biology analysis and through subscription access to its software tools for life sciences researchers and pharmaceutical developers.

Product overview

Resolve BioSciences offers Molecular Cartography, a spatial biology platform comprising hardware instruments (MC1 and MC2 benchtop platforms) and a suite of complementary software tools. The platform is built on single-molecule fluorescence in situ hybridization (smFISH) and provides multi-modal profiling of RNA, protein, and morphology on the same tissue section. Software offerings include ReCognize for 3D data visualization and cloud-based single-cell analysis, and Panel Design Studio for custom gene panel creation. The company was founded in 2020 and is headquartered in Monheim am Rhein, Germany.

Differentiator

Problem solved

Functional benefit

Brands

  • Molecular Cartography™: The company's core technology platform for multi-modal spatial profiling with unparalleled sensitivity and specificity, providing true single-molecule RNA fluorescence in situ hybridization for spatial biology analysis.
  • ReCognize

Products and services

  • Molecular Cartography A spatial biology platform based on single-molecule fluorescence in situ hybridization (smFISH) that delivers high-resolution, multi-modal tissue analysis for disease pathology, neurology, oncology, and developmental biology research. Supports simultaneous profiling of RNA (up to 330 targets), protein (over 10 markers), and morphology (H&E) on the same tissue section without tissue clearing or signal amplification; intended for research institutions, pharmaceutical companies, and academic laboratories.
  • MC1 Benchtop Platform First-generation benchtop instrument of the Molecular Cartography platform for spatial molecular imaging, performing targeted RNA and protein assays on tissue samples with high sensitivity and specificity. Used by research institutions, pharmaceutical companies, and academic laboratories performing spatial biology experiments.
  • MC2 Next-Generation Benchtop Platform Next-generation benchtop instrument of the Molecular Cartography platform offering expanded scanning area, increased plexity, targeted panel content, advanced controls, and true multi-modality compared to MC1. Designed for next-generation pathology workflows in research and translational settings.
  • ReCognize Web-based, all-in-one data visualization and analysis application for Molecular Cartography data. Browses expression data in 3D, automatically builds cell-by-gene expression matrices from uploaded ROI files, performs cell clustering via Seurat in the cloud, generates UMAP visualizations, heatmaps, and exports annotated images and CSV transcript counts. Accessed by registered customers through the My Resolve portal.
  • Panel Design Studio Web-based design tool within the My Resolve portal for building custom gene panels by selecting genes, defining probe-sets, and simulating theoretical expression levels across human tissues and cell types using data from The Human Protein Atlas. Used by researchers designing Molecular Cartography RNA experiments.
  • Molecular Cartography RNA Assay Spatial transcriptomics assay that uses in-silico designed probes and combinatorial labeling across multiple rounds of hybridization and imaging to detect up to 330 RNA targets per tissue section at subcellular resolution, applied in tumor biology, neurology, and developmental biology research.
  • Molecular Cartography Protein Assay Cyclic immuno-fluorescence workflow detecting over 10 protein markers per sample, complementing RNA data for multi-omic analysis ranging from investigational to routine clinical applications, applied in tumor pathology and immuno-oncology research.

Quantifiable outcome

  • Detection of up to 330 RNA targets per tissue section in single run
  • +2 more outcomes

Companies that use Resolve BioSciences

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Resolve BioSciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Resolve BioSciences partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Resolve BioSciences competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: Direct competitor in spatial biology with Xenium (in situ) and Visium (capture-based) platforms; serves overlapping pharma and academic customers and is the most commercially entrenched player in the spatial transcriptomics market.
  • NanoString Technologies: Direct competitor offering GeoMx digital spatial profiling and cosMx high-plex in situ platform; targets the same oncology, immuno-oncology, and translational research customer base as Resolve.
  • Vizgen: Direct competitor based on MERFISH technology for high-plex spatial transcriptomics; competes head-to-head with Resolve's Molecular Cartography in academic and pharma research accounts.
  • Akoya Biosciences: Direct competitor in spatial biology offering the PhenoCycler (CODEX) and PhenoImager platforms for multiplexed protein and RNA spatial analysis; serves overlapping translational and pharma customers.

Emerging players

  • Rebus Biosystems: Emerging spatial transcriptomics player offering the Rebus Esper instrument with a focus on high-plex, single-cell-resolution spatial RNA profiling; competes with Resolve in research-use accounts.
  • Singular Genomics: Emerging spatial biology and multi-omics platform player with the G4 sequencing platform and spatial initiatives; partial overlap with Resolve in spatial transcriptomics-adjacent workflows.

Broad incumbents

  • Bio-Techne: Broader life-science tools incumbent with RNAscope in situ hybridization technology and a portfolio spanning reagents, instruments, and spatial biology assets (including acquired brands); competes with Resolve in the spatial RNA workflow layer.
  • Bruker: Diversified scientific instrument maker that has expanded into spatial biology through acquisitions (e.g., NanoString's spatial assets); competes with Resolve as a broad incumbent entering the spatial transcriptomics market.
  • Standard BioTools: Life-science tools company with mass cytometry and spatial biology offerings; less direct overlap but competes for the same translational and pharma research budgets as Resolve.
  • Illumina: Sequencing giant with downstream spatial-adjacent offerings (e.g., partnerships and DRAGEN software for spatial data); represents both a potential partner and a competitive threat given its reach into pharma genomic workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Resolve BioSciences social profiles

Digital presence

Resolve BioSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Resolve BioSciences leadership team

Management profile

Number of profiles

Profiles8 records

Resolve BioSciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Resolve BioSciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resolve BioSciences

What does Resolve BioSciences do?

Resolve BioSciences delivers a Molecular Cartography™ spatial biology platform built on single-molecule fluorescence in situ hybridization (smFISH), enabling high-resolution, multi-modal profiling of RNA (up to 330 targets), protein (10+ markers), and H&E morphology on the same tissue section without tissue clearing or signal amplification. Offerings include the MC1 and MC2 benchtop instruments, RNA and protein assays, deep learning–based cell segmentation, the ReCognize cloud-based 3D visualization application, and the Panel Design Studio for custom gene panel creation. The company provides these capabilities primarily as fee-for-service spatial biology analysis and through subscription access to its software tools for life sciences researchers and pharmaceutical developers.

Is Resolve BioSciences a public or private company?

Resolve BioSciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Resolve BioSciences founded?

Resolve BioSciences was founded in 2020. It employs 51 to 100 people.

Where is Resolve BioSciences based?

Resolve BioSciences is headquartered in Monheim am Rhein, Germany, in the Europe region.

How does Resolve BioSciences make money?

Two revenue lines are on record. Molecular Cartography Platform Services are the primary driver. The others are software and Data Analysis Tools.

Who are Resolve BioSciences's main competitors?

Direct peers on record are 10x Genomics, NanoString Technologies, Vizgen and Akoya Biosciences. Emerging players are Rebus Biosystems and Singular Genomics. Broad incumbents are Bio-Techne, Bruker, Standard BioTools and Illumina.

Does Resolve BioSciences have an API?

No public API is recorded for Resolve BioSciences.

What industry is Resolve BioSciences in?

Resolve BioSciences's product category is Spatial Biology / Spatial Transcriptomics. Its primary akta.pro industry code is HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling), with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceResolve Biosciences Announces Appointment of John Stark as Chief Executive OfficerResolve Biosciences appointed John Stark as CEO, replacing Jason Gammack. Stark previously led Quantum-Si and Celsee, bringing over 20 years of experience. The company, based in Germany, focuses on Molecular Cartography technology for spatial biology.Business Wire BlogResolve Biosciences Announces Appointment of John Stark as Chief Executive OfficerResolve Biosciences appointed John Stark as CEO, replacing Jason Gammack. Stark previously led Quantum-Si and Celsee, bringing over 20 years of life sciences leadership. The company, based in Germany, focuses on Molecular Cartography technology for spatial biology.Business Wire BlogResolve Biosciences Expands Meridian Molecular Cartography™ Service Program for Virtually Any Species or Tissue Type at AGBT 2023Resolve Biosciences expanded its Meridian Molecular Cartography service to accept fresh-frozen, fixed, and FFPE tissue samples, enabling scientists without their own system to access its spatial transcriptomics technology. The company will add FFPE capabilities to its commercial systems later this year and will showcase the program at AGBT 2023.BioSpaceResolve Biosciences Appoints Chief Commercial Officer to Drive Worldwide Adoption of Molecular Cartography™ WorkflowResolve Biosciences appointed Paul Steinberg as Chief Commercial Officer to drive worldwide adoption of its Molecular Cartography workflow. The appointment follows a $71 million Series B financing round led by Patient Square Capital. Steinberg will lead global sales, technical service, business development, and marketing.ForbesThis Company Just Raised $71 Million To See The Forest For The Trees Within A Patient’s CellsResolve Biosciences raised $71 million in a Series B round led by Patient Square Capital, bringing total backing to over $100 million. The spatial biology company plans to scale commercialization and advance product development with the funds.Business Wire BlogResolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ WorkflowResolve Biosciences secured $71 million in Series B financing led by Patient Square Capital, bringing total funding to over $100 million. The company will use the proceeds to scale operations and accelerate product development for its Molecular Cartography workflow, which has been installed in multiple laboratories.FinSMEsResolve Biosciences Raises $71M in Series B FinancingResolve Biosciences raised $71 million in Series B funding led by Patient Square Capital to scale operations and accelerate product development. The company, which has now secured over $100 million in total financing, utilizes Molecular Cartography technology for spatial biology research in fields such as oncology and neuroscience. This capital injection supports the expansion of its global demand capabilities.BioSpaceResolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ WorkflowResolve Biosciences has secured $71 million in Series B financing led by Patient Square Capital to accelerate commercial expansion and product development. The company plans to use these funds to scale operations and meet growing global demand for its Molecular Cartography™ spatial biology technology, which has already been installed in leading laboratories across Europe and North America.BioSpaceResolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ WorkflowResolve Biosciences launched its commercial Molecular Cartography workflow and installed first systems at VIB, DKFZ, Stanford, and the University of Copenhagen. The system provides subcellular spatial gene expression, and scientists at VIB used it to identify a new macrophage subset in fatty liver disease.BioSpaceResolve Biosciences Appoints Oliver Dick as Chief Operating OfficerResolve Biosciences appointed Oliver Dick as Chief Operating Officer, reporting to CEO Jason T. Gammack. Dick will oversee scaling of manufacturing, supply chain, and logistics to meet growing demand for the Molecular Cartography platform. He previously served as COO at Miltenyi Biotec and VP of Global Manufacturing at QIAGEN.